CA3086866C - Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke - Google Patents

Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke Download PDF

Info

Publication number
CA3086866C
CA3086866C CA3086866A CA3086866A CA3086866C CA 3086866 C CA3086866 C CA 3086866C CA 3086866 A CA3086866 A CA 3086866A CA 3086866 A CA3086866 A CA 3086866A CA 3086866 C CA3086866 C CA 3086866C
Authority
CA
Canada
Prior art keywords
hemorrhage
surgery
caused
compound
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3086866A
Other languages
English (en)
French (fr)
Other versions
CA3086866A1 (en
Inventor
Guangmei Yan
Yijun Huang
Wei Yin
Suizhen LIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Cellprotek Pharmaceutical Co Ltd
Original Assignee
Guangzhou Cellprotek Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Cellprotek Pharmaceutical Co Ltd filed Critical Guangzhou Cellprotek Pharmaceutical Co Ltd
Publication of CA3086866A1 publication Critical patent/CA3086866A1/en
Application granted granted Critical
Publication of CA3086866C publication Critical patent/CA3086866C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3086866A 2017-12-29 2018-12-28 Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke Active CA3086866C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711479490.8 2017-12-29
CN201711479490.8A CN109985047B (zh) 2017-12-29 2017-12-29 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用
PCT/CN2018/124707 WO2019129181A1 (zh) 2017-12-29 2018-12-28 化合物在制备治疗出血性脑卒中药物中的应用

Publications (2)

Publication Number Publication Date
CA3086866A1 CA3086866A1 (en) 2019-07-04
CA3086866C true CA3086866C (en) 2022-08-16

Family

ID=67063234

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3086866A Active CA3086866C (en) 2017-12-29 2018-12-28 Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke

Country Status (12)

Country Link
US (1) US11382921B2 (zh)
EP (1) EP3733189A4 (zh)
JP (1) JP7007487B2 (zh)
KR (1) KR102475179B1 (zh)
CN (2) CN109985047B (zh)
AU (1) AU2018396897B2 (zh)
BR (1) BR112020013308A2 (zh)
CA (1) CA3086866C (zh)
IL (1) IL275687A (zh)
RU (1) RU2752090C1 (zh)
TW (1) TWI757573B (zh)
WO (1) WO2019129181A1 (zh)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783564A (en) * 1993-12-24 1998-07-21 Mitsubishi Chemical Corporation Sialic acid derivatives
JP3990387B2 (ja) * 2004-06-25 2007-10-10 独立行政法人科学技術振興機構 ヒソップ抽出物の血液流動性改善剤、血流改善剤およびその利用
WO2007013842A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
CA2774197A1 (en) * 2006-04-22 2008-04-03 Harbor Biosciences, Inc. Drugs and uses to modulate inflammation, metabolic disorders and other conditions
PL2486924T3 (pl) 2006-04-22 2019-07-31 Neurmedix, Inc. Leki i zastosowania
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
CN102180928B (zh) 2011-03-15 2013-01-16 广州市赛普特医药科技有限公司 3β,5α,6β-三羟基甾体化合物及其合成方法和应用
WO2012138590A1 (en) * 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN102764280A (zh) * 2011-05-06 2012-11-07 秦引林 含有牛黄，麝香的药物组合及其应用
KR20200057802A (ko) * 2011-12-13 2020-05-26 노노 인코포레이티드 지주막하 출혈 및 허혈에 대한 치료법
US20140127185A1 (en) * 2012-11-02 2014-05-08 Emory University Methods and compositions using neuroprotective steroids and thrombolytic agents
CN103333216A (zh) * 2013-06-04 2013-10-02 苏州大学 5α-6-酮-胆甾烷类似物及其应用
CN104288110B (zh) 2013-06-26 2017-05-10 广州市赛普特医药科技股份有限公司 5α‑雄甾‑3β,5,6β‑三醇注射剂及其制备方法

Also Published As

Publication number Publication date
TW201929862A (zh) 2019-08-01
RU2752090C1 (ru) 2021-07-22
JP7007487B2 (ja) 2022-01-24
KR102475179B1 (ko) 2022-12-07
US11382921B2 (en) 2022-07-12
CN109985047A (zh) 2019-07-09
US20210060035A1 (en) 2021-03-04
CN113350359A (zh) 2021-09-07
CA3086866A1 (en) 2019-07-04
EP3733189A1 (en) 2020-11-04
WO2019129181A1 (zh) 2019-07-04
AU2018396897A1 (en) 2020-07-30
CN109985047B (zh) 2021-07-27
CN113350359B (zh) 2022-08-16
IL275687A (en) 2020-08-31
BR112020013308A2 (pt) 2020-12-01
EP3733189A4 (en) 2021-10-20
KR20200104357A (ko) 2020-09-03
AU2018396897B2 (en) 2021-08-05
JP2021507933A (ja) 2021-02-25
TWI757573B (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
EP3043785B1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
US9670139B2 (en) Telomerase activating compounds and methods of use thereof
ES2376793T3 (es) Tratamiento o prevención de trastornos hipertensivos del embarazo o retraso del crecimiento fetal
BR112013019352A2 (pt) método para o tratamento de lipodistrofia, uso de um composto, dosagem diária, método de tratamento, composição farmacêutica, uso da composição farmacêutica e composto
JP5605659B2 (ja) 細胞保護剤
US11116789B2 (en) Compositions and methods for pain relief without numbness
TW201737943A (zh) 使用fasn抑制劑之方法
BR112020000989A2 (pt) métodos e composições para tratamento de dor com o uso de capsaicina
JP2019522666A (ja) ２型糖尿病の治療のためのアドレナリン受容体アゴニストの併用
NO327145B1 (no) Blanding for nasal administrasjon omfattende metansulfonat-saltet av morfin og kitosan.
CA3086866C (en) Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke
JP2015509931A (ja) 医薬的な組み合わせ
ES2423866B1 (es) Composición farmaceútica de ibuprofeno y tramadol para inyección
TW201813639A (zh) 氯硝柳胺及其衍生物的用途
JP5837128B2 (ja) カルボスチリルとカルニチンの組み合わせ医薬
JP2019509321A (ja) 疼痛を処置するための組み合わせ
BR112020013318A2 (pt) uso de um composto de fórmula i ou um composto deuterado ou um sal farmaceuticamente aceitável deste na manufatura de um medicamento para o tratamento de doença de pequenos vasos cerebrais em um paciente
JP7219476B2 (ja) 腱滑膜病変を主体とした疾患の治療薬
Mir et al. TO INVESTIGATE THE IMPACT OF INTRATHECAL ADMINISTRATION OF DEXMEDETOMIDINE AND CLONIDINE AS ADJUVANTS AGENTS TO 0.5% HYPERBARIC BUPIVACAINE DURING SPINAL ANAESTHESIA: A COMPARATIVE STUDY
Zhan et al. A Case of Severe Postop-erative Agitation and Literature Review
JP2024520650A (ja) 特発性肺線維症の処置におけるカプサイシン誘導体
CN103610676B (zh) 4-((吡啶-3-羧基)-氨基)-丁酸或其盐在制备治疗男性性功能***障碍疾病药物中的应用
CN117771392A (zh) 一种gpr65激动剂和aav病毒在用于制备治疗脑缺血性疾病的药物组合上的用途及药物组合
TW200800157A (en) Alpha-2-delta ligands for non-restorative sleep

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200624

EEER Examination request

Effective date: 20200624

EEER Examination request

Effective date: 20200624